What they were paid
HAEMONETICS Director Compensation Table · all 3 fiscal years held| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2026 | $90,000 | $199,982 | $0 | $0 | $289,982 |
| FY2025 | $80,000 | $199,954 | $0 | $0 | $279,954 |
| FY2024 | $52,609 | $199,984 | $0 | $0 | $252,593 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: HAEMONETICS CORP DEF 14A filed June 9, 2026, accession 0000313143-26-000074, and prior-year filings. Open the filing on EDGAR.
How this board is paid
company policy · FY2026HAEMONETICS pays directors a $55,000 cash retainer and $200,000 in RSUs.
Committees
FY2026 · as the proxy prints themCompensation · Technology
The rest of the HAEMONETICS board
FY2026 · as the company reported each| Director | Role | FY2026 total |
|---|---|---|
| Charles J. Dockendorff | Independent Director | $299,232 |
| Christopher A. Simon | Director | $0 |
| Claire Pomeroy | Independent Director | $299,982 |
| Ellen M. Zane | Chair of the Board | $449,982 |
| Lloyd E. Johnson | Independent Director | $306,732 |
| Mark W. Kroll | Independent Director | $289,982 |
| Michael J. Coyle | Independent Director | $292,982 |
| Robert E. Abernathy | Independent Director | $304,982 |
The full HAEMONETICS compensation record
free company briefThis page is one director within HAEMONETICS's record. The company brief lists every named executive and director, each linking to their own page.
Velarion Pro: every company page, peer tools and exports, one seat